Last reviewed · How we verify
Extrinsic allergic alveolitis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Prelone | prednisolone | Generic (originally Schering) | Glucocorticoid (corticosteroid) | Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 | 1955-01-01 | |
| prednisolon | prednisolon | Hannover Medical School | Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Generic (originally Schering) · 1 drug in Extrinsic allergic alveolitis
- Hannover Medical School · 1 drug in Extrinsic allergic alveolitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Extrinsic allergic alveolitis:
- Extrinsic allergic alveolitis treatment updates — RSS
- Extrinsic allergic alveolitis treatment updates — Atom
- Extrinsic allergic alveolitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Extrinsic allergic alveolitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/extrinsic-allergic-alveolitis. Accessed 2026-06-10.
Related
- Extrinsic allergic alveolitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing